(Q57912180)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Affinity reagents against tumour-associated extracellular molecules and newforming vessels (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

Zardi L

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 April 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

Advanced Drug Delivery Reviews

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

43-52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Stromal involvement in malignant growth

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

How does extracellular matrix control capillary morphogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Transformed human cells release different fibronectin variants than do normal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Differential expression of the fibronectin isoform containing the ED-B oncofetal domain in normal human fibroblast cell lines originating from different tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Alternative splicing of chicken fibronectin in embryos and in normal and transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Expression of the alternatively spliced EIIIB segment of fibronectin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Single-chain antigen-binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

The influence of polyvalency on the binding properties of antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Antibody framework residues affecting the conformation of the hypervariable loops

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Making antibody fragments using phage display libraries

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Phage antibodies: filamentous phage displaying antibody variable domains

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Isolation of high affinity human antibodies directly from large synthetic repertoires.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Making antibodies by phage display technology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

By-passing immunization: building high affinity human antibodies by chain shuffling

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Selection of phage antibodies by binding affinity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Biophysical methods for the determination of antibody-antigen affinities

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Immunotoxins: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Antibody-targeted photolysis of bacteria in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

A recombinant single chain antibody interleukin-2 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

Mix and match: building manifold binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900093-8

7 January 2021

10.1016/S0169-409X(97)00093-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837617%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference